Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years

Exclusion Criteria

• •1. History of microbiologically proven invasive pneumococcal disease (IPD) caused by S. pneumoniae within 3 years before study intervention administration.
• •2. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
• •3. Any confirmed or suspected immunosuppressive or immunodeficient condition.
• •4. Hypersensitivity to latex.
• •5. Clinical conditions representing a contraindication to intramuscular vaccination, and blood collection.
• •6. Documented HIV-positive status.
• •7. Acute or unstable chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, or metabolic conditions as determined by the investigator.
• •8. Recurrent history of uncontrolled neurological or any neuroinflammatory disorders.
• •9. Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.
• •10. Any other clinical condition that, might pose additional risk to the participant.
• •11. Use of any investigational or non-registered product other than the study interventions within 30 days before the study intervention administration.
• •12. History of previous vaccination with any pneumococcal vaccine.
• •13. Administration of immunoglobulins or other blood products or plasma derivatives within 90 days before or planned within 30 days after study intervention.
• •14. Chronic administrations of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the trial.
• •15. Pregnant or lactating female participant.
• •16. History of and/or current chronic alcohol consumption and/or drug abuse, based on investigator judgment.